Sales of Statin/Ezetimibe have surpassed ₩600 billion

Last year, the amount of outpatient prescriptions quadrupled to ₩609.9 billion in five years

Sales of Atorvastati/Ezetimibe rose 56% year-on-year to ₩128.8 billion

In the dyslipidemia treatment market, a combination of Statin + Ezetimibe is gaining explosive popularity.

 

The annual prescription market has more than quadrupled over the past five years, exceeding 600 billion won.

 

Rosuvastatin +Ezetimibe is leading the market growth.

 

According to UBIST, a pharmaceutical research institute, the amount of outpatient prescriptions for Statin +Ezetimibe was 609.9 billion won, up 23.1% from the previous year.

 

It increased 52.3% in two years from 40.4 billion won in 2019.

 

It showed rapid growth every year from 136.9 billion won in 2016 to 345.4% in five years.

 

Sales of Rosuvastatin and Ezetimibe are forming the largest market.

 

Last year, the prescription amount of Rosuvastatin and Ezetimibe was 436.3 billion won, up 18.8% from the previous year.

 

The market size has more than tripled in five years from 56 billion won in 2016.

 

Rosuvastatin and Ezetimibe account for 71.5% of Statin and Ezetimibe market.

 

The market for Rosuvastatin and Ezetimibe began in 2015 when Hanmi Pharmaceutical launched Rosuzet.

 

Rosuzet recorded a prescription performance of 123.2 billion won last year, up 17.4% from the previous year, contributing the most to the expansion of Statin and Ezetimibe markets.

 

Hanmi Pharmaceutical has secured the right to use Ezetimibe from MSD and has recorded high growth rates since entering the market before its competitors, ranking first in the same ingredient market.

 

Rosuzet ranked second among all medicines.

 

For the first time in 2020, it exceeded 100 billion won in prescriptions and was named the "100 billion won club" for the second consecutive year.

 

Last year, it ranked second in prescription amount after Lipitor among all medicines.

 

A total of 10 companies recorded more than 10 billion won in prescriptions last year, playing a role as a cash cow.

 

Yuhan Corporation's Rosuvamibe rose 7.8% from the previous year to 62 billion won in prescriptions last year.

 

HK inno.N, GC Pharma, Daewoong, Huons, Jeil, Kyung Dong, Hutechs, and Myungmoon recorded more than 10 billion won in prescription amount in the Rosuvastatin and Ezetimibe market last year.

 

Last year, Atorvastatin-Ezetimibe market showed great growth.

 

The prescription amount of Atorvastatin-Ezetimibe was 128.8 billion won, up 55.6% in a year from 82.8 billion won in 2020.

 

With the release of a huge number of Atozet's generics, the market size expanded in a short period of time.

 

MSD's Atozet was the only one generic until 2020.

 

Since last year, the size of the market has risen significantly as more than 100 domestic companies have joined at the same time.

 

In October 2020, Chong Kun Dang's Lipilouzet went through a clinical trial in October last year and was approved.

 

At this time, 22 companies' generics for Lipilouzet were approved and were listed from April last year.

 

Since February last year, 88 additional pharmaceutical companies' generic for Atozet have started to be approved.

 

Since January 22, when Atozet's review period expired, it has been approved for sale simultaneously since applying for permission and registered in May, a month later than generic for Lipilouzet.

 

As Korus Pharm and Mirae Pharm were approved for generics for Atozet in June last year, the number of domestic companies that have entered the Atozet market over the past year has increased to 113.

 

Sales of Simvastatin+Ezetimibe slowed down.

 

Last year, the prescription amount of the Simvastatin+Ezetimibe was 43 billion won, down 5.3% from the previous year.

 

It is down 23.6% from five years ago.

 

Simvastatin+Ezetimibe, the original product of MSD's Vytorin, was first released in Statin-Etimibe market, but its growth is stagnant.

 

Amount of outpatient prescriptions for Statin + Ezetimibe by year (unit: 100 million won, data: UBIST)